Catheter News and Research RSS Feed - Catheter News and Research

In medicine, a catheter is a tube that can be inserted into a body cavity, duct, or vessel. Catheters . In most uses, a catheter is a thin, flexible tube ("soft" catheter), though in some uses, it is a larger, solid ("hard") catheter. A catheter left inside the body, either temporarily or permanently, may be referred to as an indwelling catheter. A permanently inserted catheter may be referred to as a permcath.
Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%. [More]

Hospital sees success by temporarily connecting major blood vessels

Doctors at Henry Ford Hospital reached a medical milestone April 3, performing the 25th successful transcatheter valve replacement using a novel way to access the heart. [More]
Expert guidance highlights strategies to prevent catheter-associated urinary tract infections

Expert guidance highlights strategies to prevent catheter-associated urinary tract infections

New expert guidance highlights strategies for implementing and prioritizing efforts to prevent catheter-associated urinary tract infections (CAUTI) in hospitals. [More]
Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE). [More]

Aortic valve replacement now possible without open-heart surgery

Loyola University Medical Center is the first hospital in Illinois to implant a newly approved aortic heart valve device that does not require open surgery. [More]
Ablative Solutions’ Peregrine System Infusion Catheter receives FDA clearance

Ablative Solutions’ Peregrine System Infusion Catheter receives FDA clearance

Ablative Solutions, Inc., a privately-held clinical stage company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Peregrine System(TM) Infusion Catheter. [More]

Ablative Solutions' Peregrine System Infusion Catheter receives FDA clearance

Ablative Solutions, Inc., a privately-held clinical stage company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration for its Peregrine System™ Infusion Catheter. [More]
Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX) reported favorable results in studies related to cardiac resynchronization therapy (CRT), platinum chromium stent platforms and transcatheter aortic valve replacement (TAVR). [More]

Study of non-surgically implanted replacement pulmonary valve shows strong results

The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in patients with certain congenital heart defects, according to research presented by a U-M pediatric interventional cardiologist at the American College of Cardiology's 63rd Annual Scientific Session Sunday. [More]
Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]

SEATTLE II study confirms safety and efficacy of thrombolytic therapy for acute PE

EKOS Corporation, a BTG International group company, notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States. [More]

Study compares two types of heart valve technologies

Among patients undergoing aortic valve replacement using a catheter tube, a comparison of two types of heart valve technologies, balloon-expandable or self-expandable valve systems, found a greater rate of device success with the balloon-expandable valve, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. [More]
New urinary catheter design can eliminate nearly all hard-to-kill biofilm

New urinary catheter design can eliminate nearly all hard-to-kill biofilm

For the millions of people forced to rely on a plastic tube to eliminate their urine, developing an infection is nearly a 100 percent guarantee after just four weeks. But with the help of a little bubble-blowing, biomedical engineers hope to bring relief to urethras everywhere. [More]

United Therapeutics' Remodulin Injection gets approval in Japan for PAH treatment

United Therapeutics Corporation today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration. [More]
Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

Protein known to promote cancer appears to give blood vessels strength and shape, researchers report

A protein known to promote cancer appears to give the blood vessels strength and shape, researchers report. When yes-associated protein, or YAP, is deleted from vascular smooth muscle cells during development, the protein makes thin-walled blood vessels that over-dilate in response to the usual pressure of blood flow, said Dr. Jiliang Zhou, vascular biologist at the Medical College of Georgia at Georgia Regents University. [More]

St. Jude Medical announces first enrollments in LEADLESS Pacemaker Observational Study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollments in the company’s LEADLESS Pacemaker Observational Study evaluating the Nanostim leadless pacing technology. The Nanostim pacemaker received CE Mark in 2013, and post-approval implants have occurred in the UK, Germany, Italy, Czech Republic, France, Spain, and the Netherlands. [More]

New standard for U.S. heart transplantation

The Cedars-Sinai Heart Institute has set a new standard for U.S. heart transplantation by completing 117 adult heart transplants and two adult heart-lung transplants, for a total of 119 adult heart transplants in a single year. The previous number set in 2005, was 98 adult heart transplants performed in one year. [More]
Stem cell therapy may benefit patients with debilitating heart failure

Stem cell therapy may benefit patients with debilitating heart failure

Researchers want to know whether patients with debilitating heart failure can benefit by having their own stem cells injected into their ailing heart muscle. [More]
Hepatitis C drug fuels cost debate

Hepatitis C drug fuels cost debate

A panel of experts said this week that the drug represents a "low value" to the health system because of its cost. [More]